Live Webinar

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

Hosted by AJMC, Managed Healthcare Executive, Pharmacy Times and PBMI

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
  • News
  • Watch
  • Journals
  • Conferences
  • Events
  • Resources
  • CE
  • About AJMC
  • Subscribe
|Articles|July 1, 1998

Supplements and Featured Publications

  • New and Emerging Therapies in the Treatment of Hypertension and Congestive Heart Failure
  • Volume 4
  • Issue 7 Suppl

The Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure

Download PDF: The Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure

Articles in this issue

about 28 years ago

Participating Faculty

about 28 years ago

Introduction: Current Concepts in Hypertension Management and A Look Toward the Future

about 28 years ago

Gene Polymorphism Influences Response to Angiotensin Blockade

about 28 years ago

New Drug Class Offers Benefits in Heart Failure

about 28 years ago

Comparative Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blocking Agents on Left Ventricular Volumes in Elderly Patients with Heart Failure

about 28 years ago

Phase I Results of the Randomized Evaluation of Left Ventricular Dysfunction (RESOLVD) Trial

about 28 years ago

European Society of Cardiology: Angiotensin II Antagonists: Why is There So Much Excitement?

about 28 years ago

What are the Pharmacological Differences Between Angiotensin II Antagonists

about 28 years ago

Clinical Implications of Differences Between Angiotensin II Antagonists

about 28 years ago

Exploring the Benefits Beyond Blood Pressure Control

Related Content